Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neutrogena T-Gel use with Merck's Propecia Rx baldness drug suggested by FDA cmte.

This article was originally published in The Tan Sheet

Executive Summary

NEUTROGENA T-GEL/MERCK PROPECIA CONCOMITANT USE RECOMMENDED for the Rx baldness treatment by FDA's Dermatologic & Ophthalmic Drugs Advisory Committee during the group's Nov. 13 review of the oral hair regrowth drug finasteride. FDA had asked the committee to consider the effect of Neutrogena's OTC coal tar dandruff shampoo "on the assessment of the treatment response to Propecia." T-Gel was used in both the treatment and control groups of Merck's safety and efficacy trial for Propecia as a prophylaxis for seborrheic dermatitis, which, according to the company, is a condition often seen in balding men. The recommended dose of T-Gel during the trial was not specified.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel